• HOME
  • ABOUT IASO
    • Overview
    • Management Team
    • Scientific Advisory Board
    • Partnership
  • SCIENCE & PRODUCTS
    • Publictaions
    • Technology Platforms
    • Pipeline
    • Manufacturing
  • NEWS
    • Press Release
    • Media Report
  • CAREERS
    • Growth & Development
    • Working at IASO
    • Opportunities
  • CONTACT
    • 中文简体
    • 中文繁体
    • English

We always innovate to
deliver cures
to global patients

We are focused on development of 

novel cell therapies for oncology and 

autoimmune diseases

Our Culture

Well-established end-to-end R&D platform and proprietary manufacturing site

  • Pipeline

    We are committed to developing cell therapies and antibody drugs. we now have a diverse pipeline

  • Technology platform

    We have a well-established end-to-end R&D platform and proprietary manufacturing site

  • Manufacturing

    Our mature and stable CMC platform technology enables large-scale, high-quality manufacturing

News

13/062022

IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy(Equecabtagene Autoleucel)at EHA 2022

02/062022

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

20/052022

IASO Biotherapeutics’ Equecabtagene Autoleucel, the World’s First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA

More
  • ABOUT IASO

    OverviewManagement TeamScientific Advisory BoardPartnership
  • SCIENCE & PRODUCTS

    PublictaionsTechnology PlatformsPipelineManufacturing
  • NEWS

    Press ReleaseMedia Report
  • CAREERS

    Growth & DevelopmentWorking at IASOOpportunities
  • CONTACT

Copyright © 2021 南京驯鹿医疗技术有限公司     苏ICP备2021047135号     Privacy Policy | Terms of Use